Dr. Reddy’s Laboratories along with several other pharmaceutical companies, was named as a defendant in a complaint filed on November 8, 2023, in the United States District Court for the District of New Jersey.

The complaint, filed by Intermountain Health, asserts claims under federal and state antitrust laws and other state laws alleging that the defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid through their respective settlements of patent litigation.

The complaint alleges that the challenged agreements improperly delayed generic entry entirely until 2022 and then improperly limited generic competition through 2026. The complaint seeks damages for purported overpayments and equitable relief.

Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation.